Summary
Schnell Biopharmaceuticals, Inc. (Schnell) is a manufacturer of pharmaceutical products. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants; musculoskeletal system agents, consisting of anti-inflammatory drugs, muscle relaxants, respiratory system agents, including expectorants, antitussives and antihistamines. Schnell also produces vitamins and nutrition agents. The company provides the other drugs such as antiemetics and antineoplastic agents. It operates through its factory located in Hwaseong-si, Korea. Schnell is headquartered in Seongnam, Republic of Korea.
Schnell Biopharmaceuticals, Inc. (003060) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Binex Forms Joint Venture with Aprogen 11
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 12
Licensing Agreements 13
Schnell BioPharma Enters Into Licensing Agreement With Aquapick 13
Schnell BioPharma Enters Into Licensing Agreement With AVVA 14
Equity Offering 15
Schnell BioPharma Completes Private Placement Of US$3.3 Million 15
Schnell BioPharma Completes Rights Offering Of Common Stock For US$3.6 Million 17
Debt Offering 18
Schnell BioPharma Completes Issue Of Ninth Unsecured Bonds Due 2014 For US$8.8 Million 18
Schnell BioPharma Completes Issue Of Eighth Unsecured Bonds Due 2014 For US$14.5 Million 19
Schnell BioPharma Completes Offering Of Seventh Unsecured Bonds Due 2013 For US$8.48 Million 20
Acquisition 21
Huacheng Travel Agency Plans to Acquire Schnell Biopharma 21
Gbase to Acquire 22% Stake in Aprogen for USD16 Million 22
Binex Completes Acquisition of 22% Stake in Aprogen for USD14 million 23
Schnell Biopharma Sells 50% Stake In CHUNG GEI Pharma For US$6.5 Million 25
Nichi-iko Pharma Acquires 33.4% Stake In Aprogen 26
Schnell BioPharma Acquires Remaining 39% Stake In Chunggei Pharm 27
Schnell Biopharmaceuticals, Inc. - Key Competitors 28
Key Employees 29
Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List of Tables
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Schnell Biopharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Binex Forms Joint Venture with Aprogen 11
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 12
Schnell BioPharma Enters Into Licensing Agreement With Aquapick 13
Schnell BioPharma Enters Into Licensing Agreement With AVVA 14
Schnell BioPharma Completes Private Placement Of US$3.3 Million 15
Schnell BioPharma Completes Rights Offering Of Common Stock For US$3.6 Million 17
Schnell BioPharma Completes Issue Of Ninth Unsecured Bonds Due 2014 For US$8.8 Million 18
Schnell BioPharma Completes Issue Of Eighth Unsecured Bonds Due 2014 For US$14.5 Million 19
Schnell BioPharma Completes Offering Of Seventh Unsecured Bonds Due 2013 For US$8.48 Million 20
Huacheng Travel Agency Plans to Acquire Schnell Biopharma 21
Gbase to Acquire 22% Stake in Aprogen for USD16 Million 22
Binex Completes Acquisition of 22% Stake in Aprogen for USD14 million 23
Schnell Biopharma Sells 50% Stake In CHUNG GEI Pharma For US$6.5 Million 25
Nichi-iko Pharma Acquires 33.4% Stake In Aprogen 26
Schnell BioPharma Acquires Remaining 39% Stake In Chunggei Pharm 27
Schnell Biopharmaceuticals, Inc., Key Competitors 28
Schnell Biopharmaceuticals, Inc., Key Employees 29
Schnell Biopharmaceuticals, Inc., Subsidiaries 30
List of Figures
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Schnell Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
